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Epstein-Barr virus (EBV), which is associated with
multiple human tumors, persists as a minichromo-
some in the nucleus of B lymphocytes and induces
malignancies through incompletely understood
mechanisms. Here, we present a large-scale func-
tional genomic analysis of EBV. Our experimentally
generated nucleosome positioning maps and viral
protein binding data were integrated with over 700
publicly available high-throughput sequencing data
sets for human lymphoblastoid cell lines mapped to
the EBV genome. We found that viral lytic genes are
coexpressed with cellular cancer-associated path-
ways, suggesting that the lytic cycle may play an
unexpected role in virus-mediated oncogenesis.
Host regulators of viral oncogene expression and
chromosome structure were identified and validated,
revealing a role for the B cell-specific protein Pax5 in
viral gene regulation and the cohesin complex in
regulating higher order chromatin structure. Our
findings provide a deeper understanding of latent
viral persistence in oncogenesis and establish a valu-
able viral genomics resource for future exploration.
INTRODUCTION
Viruses coevolve with their hosts to establish stable and coregu-
lated genomes and gene expression programs (Iyer et al., 2006).
DNA tumor viruses are distinguished by their ability to provide
a selective growth advantage to host cells and typically establish
long-term persistent intracellular infections (Moore and Chang,
2010). Among the most extensively characterized human tumor
viruses is Epstein-Barr virus (EBV), which has been implicated
as a causative agent in multiple B cell lymphomas, gastric
carcinomas, and nasopharyngeal carcinomas (Rickinson and
Kieff, 2007; Young and Rickinson, 2004). EBV is estimated to
be responsible for1% of all human cancers and may also con-
tribute to other disorders, including multiple sclerosis (Ascherio
and Munger, 2010; Parkin, 2006). While EBV oncogenes and
regulatory pathways have been characterized individually, thereCell Hoshave been few studies that examine the network of virus-host
interactions at a genomic scale.
Methods emerging from systems biology and functional geno-
mics provide powerful approaches for elucidating these viral-
host interaction networks (Aderem et al., 2011). Chronic infection
by DNA tumor viruses, such as EBV, is particularly well suited for
systems-level interrogation. EBV genomes persist as multicopy
DNA episomes in the nucleus of human B lymphocytes (Lieber-
man, 2006; Lindner and Sugden, 2007), which can be assayed
by modern high-throughput sequencing methods. EBV infection
of primary human B lymphocytes leads to the efficient establish-
ment of continuously proliferating genetically stable human lym-
phoblastoid cell lines (LCLs). Additionally, the EBV expression
program in LCLs allows for the assay of the full repertoire of viral
latency genes, which are able to drive cellular proliferation and
survival in vitro and in vivo in immunocompromised hosts (Thor-
ley-Lawson and Gross, 2004). LCLs have also been extensively
characterized by human genetic studies, including large-scale
consortium projects such as ENCODE and HapMap (Altshuler
et al., 2010; Birney et al., 2007), which have created vast reposi-
tories of genotype, gene expression, and cellular phenotype data
that can be leveraged to better understand host and viral regula-
tory networks. The contribution of EBV to LCL genome biology
and the comprehensive mapping of functional elements of the
EBV genome have not been evaluated in these prior studies.
Previous genomics studies of human viruses have been
limited in scope, exploring novel virus discovery (Feng et al.,
2008), environmental niche characterization (Breitbart et al.,
2003; Reyes et al., 2010; Tadmor et al., 2011), in vitro protein
interactions (Calderwood et al., 2007; Dyer et al., 2008; Pinney
et al., 2009), and small-scale functional genomics. Many of these
studies have been done in herpesviruses, such as an RNA-seq
analysis of a Burkitt lymphoma cell line (Lin et al., 2010; Xu et al.,
2010), a low-density quantitative PCR (qPCR) primer array for
chromatin immunoprecipitation (ChIP) on a limited set of host
factors (e.g., CTCF and a small set of histone modifications)
(Tempera et al., 2010), and ChIP of the viral factors EBNA1(Dre-
sang et al., 2009; Lu et al., 2010) and BZLF1(Bergbauer et al.,
2010). There has also been recent exploration of the KSHV epi-
genome (Gu¨nther and Grundhoff, 2010; Stedman et al., 2008;
Toth et al., 2010), though it is unclear whether these epigenetic
controls are conserved between gammaherpesviruses.
Here, we present a large-scale functional genomic analysis of
EBV, which provides insights into viral pathogenesis and B cellt & Microbe 12, 233–245, August 16, 2012 ª2012 Elsevier Inc. 233
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Figure 1. Genomic Profiling of Epstein-Barr
Virus in Lymphoblastoid Cell Lines
(A) EBV-infected cell lines were subjected to
functional genomics assays coupled with high-
throughput sequencing, giving rise to reads that
map to the human host and viral genomes.
(B) Known functional elements of the 172 kbp viral
episome examined in this study. While we provide
all coordinates with respect to the 172 kbp refer-
ence, most LCLs were generated with the B95.8
strain, which contains a 12 kbp deletion (139–151
kbp). Unmappable loci have highly similar regions
in the human genome, corresponding to reads
that are of ambiguous origin.
(C) Short reads from hundreds of ChIP, RNA, and
other (DNase, FAIRE, MNase, HiC, etc.) se-
quencing experiments were mapped to the viral
and host genomes. For each experiment, the
percentage of aligned viral reads was determined
as a fraction of aligned human reads. An average
of more than 1%of readsmap to the viral genome,
though the percentage of viral reads can vary
across four orders of magnitude.
EBNA, EBV nuclear antigen; LMP, latentmembrane
protein; oriP, latent origin of replication; oriLyt, lytic
origin of replication; TR, terminal repeats; BHLF1,
viral lytic noncoding RNA, BamHI H leftward frag-
ment 1;BHRF1, viral BCL2homolog,BamHIH right-
ward fragment 1; BZLF1, viral lytic activating gene,
BamHI Z leftward fragment 1; RPMS1, viral gene
and promoter for BART miRNAs; RPM, reads per
million. See also Figure S1, Table S1, and Table S2.
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osome positioning maps and viral protein binding studies with
over 700 publicly available high-throughput sequencing data
sets for human LCLs that we have mapped to the EBV genome.
Many of the cell lines we examined were created by the
HapMap Project, and one of these was extensively assayed by
the ENCODE Consortium (Altshuler et al., 2010; Birney et al.,
2007). Using this massive repository of combined host and virus
data, we create a comprehensive atlas of interactions between
host factors and the EBV genome. We characterized genome-
wide binding profiles of over 60 human transcription factors,
which cluster into specific regulatory regions, suggesting combi-
natorial control of viral gene expression. We discovered host
genes that are coexpressed with viral genes and cluster into
B cell proliferation pathways. We demonstrated that the host
B cell specificity factor Pax5 plays an unexpected role in regu-
lating viral gene expression and chromatin organization. Finally,
we characterized the Cohesin-mediated spatial conformation of
the viral episome and demonstrate its relevance in gene regula-
tion through knockdown of its structural components. Our study
represents adenovoexplorationof functional elements and regu-
latorsof Epstein-Barr virusona largescale.All rawandprocessed
data are publicly available at http://ebv.wistar.upenn.edu.
RESULTS
Generating an Atlas of Functional Elements in the EBV
Genome
To generate a comprehensive atlas of functional elements for the
EBV genome, we analyzed many existing large-scale functional234 Cell Host & Microbe 12, 233–245, August 16, 2012 ª2012 Elsevigenomics data sets for EBV positive LCLs (Table S1 available
online). We examined 319 RNA-seq experiments from five
separate studies (Birney et al., 2007; Cheung et al., 2010;
Kasowski et al., 2010; Montgomery et al., 2010; Pickrell et al.,
2010), covering LCLs from 143 donors, multiple RNA size
ranges, cellular compartments and both poly(A)+ and poly(A)
transcripts. We explored DNA-binding proteins and histone
modifications and variants by incorporating more than 300
ChIP-seq experiments from the ENCODE project (Birney et al.,
2007). We also integrated cytokine peptide levels (Choy et al.,
2008) and related independent functional genomic studies
(Lee et al., 2011; Lu et al., 2010; Ramagopalan et al., 2010).
To ensure that we characterized reads of viral origin and
excluded reads from homologous human regions, we subtracted
reads mapping to the human genome prior to alignment against
the EBV genome (Figure 1). This subtraction did not affect mapp-
ability of the EBV genome since only a small number of highly
repetitive EBV elements are unmappable with reads longer than
24 nucleotides (Figures 1B and S1A–S1D). Alignments to EBV
accounted for a significant number of reads in nearly all assays
(Figure 1C and Table S2). In total, we aligned over 166 million
reads to the EBV genome, which accounted for 1.2% of all
mappable reads. As a negative control, we aligned reads from
experiments performed in uninfected cell lines and primary tissue
and found negligible alignment to EBV (Figures S1E and S1F).
Identification of Regulatory and Transcribed Elements
of Epstein-Barr Virus
To explore the overall organization of the functional EBV
genome, we summarized viral gene expression, transcriptioner Inc.
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Genomic Profiling of EBVfactor binding, histone modifications, and binding sites of the
chromatin insulator CTCF (Figure 2A). An initial overview of the
data provided several striking observations.
Viral Regulatory Elements
We identified many candidate regulatory domains of the viral
genome that were bound by transcriptional regulators and en-
riched in histone modifications. We analyzed binding profiles
for over 60 human transcription factors, including factors
involved in B cell development and viral response, such as
Pax5, Irf3, Ebf1, and NFKB. We found that at least 26 transcrip-
tion factors cumulatively have at least 109 reproducible signifi-
cant binding sites across the viral genome (Figures 2A and
S2A and Table S3). Furthermore, transcription factor binding
sites cluster into regulatory loci that are reminiscent of ‘‘hotspot’’
regions identified in othermodel organisms (Gerstein et al., 2010;
Moorman et al., 2006; Roy et al., 2010). Example clusters
occurred at promoters for actively transcribed latent transcripts
(Cp, RPMS1), as well as at the left lytic origin of replication
(OriLytL). The divergent promoters at OriLytL are partitioned
into two major clusters of binding factors (Figure 2B). The left-
ward transcript for BHLF1 has the highest RNA polymerase II
peak in the viral genome over its initiation site, which also over-
laps with known polymerase cofactors TBP and TAF1. The right-
ward promoter for BHRF1 (and the associated viral microRNAs
[miRNAs]) contains a peak enriched with several factors,
including p300, Gcn5, Bcl3, Pbx3, Egr1, Brca1, cFos, and
Chd2. We ensured that this locus did not have enrichment for
IgG or input DNA sequencing controls and that the overlap
was significant (Figures S2B and S2C). The prominent binding
of the insulator protein CTCF separates these independent
binding sites and their respective divergent promoters, consis-
tent with prior findings (Tempera et al., 2010) (Figures S2D–S2F).
Histone modifications and chromatin boundary factors, like
CTCF, are known to contribute to EBV latency regulation but
have never been assayed at high resolution (Tempera et al.,
2010). The highest measured histone modifications aggregated
to a peak at the RPMS1 promoter region, which is the transcrip-
tion initiation site for a cluster of EBV miRNAs and noncoding
RNAs (Figure 2C). CTCF binds downstream of this promoter
and appears to serve as a boundary for high-level promoter
proximal histone modifications H3K27ac and H3K4me3 (Fig-
ure 2C). We also mapped nucleosome positions in two cell lines
with different viral latency programs. Nucleosomes strongly
occupied the transcriptionally silent Cp promoter in type I Burkitt
lymphoma cell lines (which fail to express EBNA2 family genes),
while nucleosomes did not occupy the transcriptionally active
Cp in type III LCLs (which do express EBNA2 family genes)
(Figure 2D). These findings are consistent with reports that
active genes have nucleosome-free promoter regions (Zhou
et al., 2005).
Viral Transcriptome
The EBV genome is a complex patchwork of densely packed,
overlapping, and extensively alternatively spliced genes. As
expected in LCLs, the coding and transcribed noncoding
domains of the EBV genome were strongly enriched for RNA-
seq reads mapping to the latency transcripts for the EBNA
genes, latent membrane proteins, and RPMS1, as well as the
noncoding RNAs and miRNAs (Table S4). Less expectedly, we
detected very high read counts covering the BHLF1 transcript,Cell Hoswhich is typically associated with early stages of lytic-cycle
gene activation and is transcribed from the lytic origin of
replication (OriLyt). We also detected other immediate early
transcripts such as BZLF1 and BRLF1, though these were ex-
pressed at much lower levels. We were also able to verify a
recently reported viral-encoded small nucleolar RNA (Hutzinger
et al., 2009).
We characterized all RNA splice junctions by analysis of
paired end sequencing assays (Table S5). We found many
known isoforms and confirmed several recently reported
isoforms (Austin et al., 1988; Kelly et al., 2009; Lin et al., 2010).
Using deep sequencing from hundreds experiments across
multiple labs, we were able to detect dozens of isoforms,
including alternative splicing in BZLF1, the BART locus, and
multiple 50 sites that spliced to acceptors in BHRF1 and
BHLF1 (Figure 2E). The extensive usage of alternative donor
and acceptor splice sites is remarkable and may be relevant
for virus regulation and function.
RNA editing occurs in numerous host transcripts and was
recently shown to also occur in viral RNAs (Iizasa et al., 2010;
Li et al., 2011). Analysis of the many RNA-seq experiments re-
vealed that the BHLF1 RNA transcript contains a guanine nucle-
otide that differs from the expected adenine residue encoded in
the template DNA. This is consistent with classic ADAR-medi-
ated deamination editing (Iizasa et al., 2010). Specifically,
10% of RNA-seq reads (as averaged across 170 experiments
with >103 coverage) mapping to this locus contain the alterna-
tive base, whereas only one read in one DNA sequencing exper-
iment (out of n = 26 with >53 coverage) contained this alteration
(Figures 2F, S2G, and S2H). BHLF1 RNA has been implicated in
the initiation of viral DNA replication, and RNA editing may
contribute to this process (Rennekamp and Lieberman, 2011).
Heterogeneity of Viral Gene Expression and Lytic
Reactivation in LCLs
In proliferating LCLs, the EBV genome persists predominantly as
a type III latent infection, where a limited set of viral genes and
miRNAs are expressed and the genome is replicated exclusively
by host-cell replication machinery. However, all LCLs contain
subpopulations of cells undergoing various degrees of lytic-
cycle gene expression and replication, the extent of which varies
among cell populations and culture conditions (Davies et al.,
2010; Glaser et al., 1989).
We analyzed the EBV gene expression profiles of over 300
LCLs and, after quality filtering, we clustered 201 viral expression
profiles (Table S6 and the Supplemental Experimental Proce-
dures). The two main clusters correlated with canonical type III
latent and lytic-cycle patterns (Figures 3A and S3). This clus-
tering pattern was stable and consistent across multiple inde-
pendent labs using independent LCL subclones (Figures 3B
and S4). The gene expression clusters correlated with the
average EBV load, as measured by the percentage of RNA-seq
reads mapping to EBV (Figure 3A, top bar, and Figure S3) and
EBV episome copy number as assayed by an independent lab
in independent subclones (Figure 3C) (Choy et al., 2008). Since
lytic reactivation results in productive replication of the EBV
episome, this correlation is an independent validation of lytic
activity. However, we also observed disproportionately lower
expression of EBV structural and packaging genes associatedt & Microbe 12, 233–245, August 16, 2012 ª2012 Elsevier Inc. 235
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Figure 2. Transcribed and Regulatory Elements of the EBV Genome
(A) The average RNA expression profile (transformed by square root) shows unexpectedly high RNA reads of the lytic cycle-associated transcript BHLF1, in
addition to the canonical genes associated with type III latency. Also shown are the number of transcription factor binding sites and average signal of activating
histone modifications at known and candidate regulatory regions of the episome. Furthermore, CTCF segments the genome into many more domains than
previously recognized.
(B) The lytic origin of replication is highly enriched in transcription factor occupancy. The locus acts as a divergent promoter for the lytic-associated BHLF1 and
BHRF1 transcripts separated by a central CTCF binding site.
(C) Histonemodifications at the highly transcribed andmultiply processed RPMS1 promoter. A peak for H3K4me3wasmore proximal, while H3K4me1was distal
to the transcription start site. The histone variant H2A.Z can be seen at the1 and +1 nucleosomes, and downstream histones are acetylated up to the CTCF site.
(D) Nucleosome occupancy correlates with promoter silencing in different latency types. Nucleosomes have higher occupancy at Cp andWp in type I latent cells
(MutuI), where these promoters are transcriptionally silenced, relative to type III latent cells (LCLs).
(E) RNA-seq reveals transcript isoforms of BZLF1 (top) and EBNA-LP joined to BHRF1 (bottom). The BZLF1 transcript can be alternatively spliced to exclude the
coding region for the DNA binding domain, and multiple exons of EBNA-LP can act as donor splice sites to multiple acceptor splice sites in BHLF1. Percentages
are given as total of all BZLF1 transcripts and EBNA-LP transcripts, as estimated from reads that cross alternative and canonical splice junctions. BHRF1 is also
transcribed canonically from OriLyt.
(F) The BHLF1RNA transcript differs from the DNA template, suggesting RNA editing by ADAR-mediated deamination. Position 40080 is templated to be an A, but
RNA-seq reveals a significant portion of reads across 170 distinct RNA-seq experiments contain a G (p < 1 3 1071, t test; error bars indicate the SD).
See also Figure S2, Table S3, Table S4, and Table S5.
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Figure 3. Lymphoblastoid Cell Lines Cluster by Viral Reactivation Propensity
(A)We analyzed gene expression from 201 independent profiles of across 143 lymphoblastoid cell lines and found clustering into type III latency (upper left) or lytic
(lower right) gene expression programs. The lytic cluster has a higher percentage of reads mapping to EBV than the latent cluster (bar along top of heatmap). The
clustering of genes reveals association with latent and lytic cycle, which is quantified by the first principal component (bar to the left of the heatmap; Supplemental
Experimental Procedures). While many of the early-lytic genes are actively expressed, very few of the late-lytic genes required for virion formation are present,
suggesting that most reactivation may be abortive.
(B) Propensity for lytic reactivation persists in subclones. Forty-six cell line subclones were assayed in independent labs and have significantly similar latent and
lytic viral expression profiles (p < 0.0017, binomial test).
(C) EBV copy number, as assayed by qPCR in a separate lab from the RNA-seq experiments, correlates with lytic reactivation clustering and confirms the
heritability of expression program.
See also Figure S3 and Table S6.
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incomplete or abortive lytic gene reactivation occurs frequently
in LCLs.
B Cell Proliferation Pathways Are Coexpressed with
Viral Lytic Gene Expression
To better understand the dynamic intracellular environment
during viral reactivation, we examined host gene expression
and protein levels that correlate with the lytic cycle. We corre-
lated known cellular proteins, metabolic molecules, and surface
markers with the latent/lytic state. The cells lines with increased
viral lytic cycle tended to have significantly higher ATP, more
TNFa, more CCL5, less IL12, and more than double the levels
of IL10 (Figures 4A and S4) (Choy et al., 2008). While these
molecules are known B cell regulatory factors, their role in lytic
reactivation has been less well characterized.
We next used RNA-seq data to simultaneously assay host and
viral gene expression and identify cellular gene transcripts that
correlate with viral lytic phenotypes (Table S7, Table S8, and Fig-Cell Hosure S3). LCL RNA-seq was quantified using reads per kilobase of
exon per million mapped sequence reads (RPKM) to compute
a correlation between EBV lytic gene BHLF1 and human host
genes. Many viral genes were expressed at surprisingly high
levels relative to human transcripts (Figures 4B and 4C).
We found that EBV lytic gene expression correlated with many
human transcripts, for example, the WNT5B transcript (Figures
4D and S4). Searching pathway databases (Subramanian
et al., 2005), we found that several families of human genes
were significantly correlated with EBV lytic gene expression,
including pathways involved in B cell chronic lymphocytic
leukemia, interferon-alpha (INFa), WNT, and B cell receptor
signaling (Figure 4E, Supplemental Experimental Procedures,
and Table S9). An aggregate analysis of all cellular genes bound
by the viral transcription factor EBNA1, which is upregulated
during lytic reactivation (Figure S4D), revealed a statistically
significant increase in virally targeted genes during lytic viral
expression, suggesting direct viral regulation of host genest & Microbe 12, 233–245, August 16, 2012 ª2012 Elsevier Inc. 237
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Figure 4. Identification of Host Factors and Genes that Correlate with Spontaneous Lytic Reactivation
(A) Intercellular host cytokine concentrations, as measured by ELISA, are correlated with viral reactivation propensity (Holm corrected p values; error bars
indicate the SD).
(B) Specific EBV lytic and latent genes are expressed at similar levels relative to highly expressed human genes (error bars indicate the SD across the
201 samples).
(C) The EBV transcriptome is expressed at similar levels to the human transcriptome.
(D) The human WNT5B gene expression is highly correlated with the EBV lytic reactivation marker BHLF1.
(E) Human genes that correlate with BHLF1 fall into distinct signaling pathways, including B cell receptor (BCR), interferon alpha (IFN-a), Wnt, and B cell chronic
lymphocytic leukemia (BCLL) signaling pathways. These pathways represent an amalgamation of EBV-affected alterations and cellular antiviral response
mechanisms to increased viral load.
(F) The viral transcription factor EBNA1 (EBV-encoded nuclear antigen 1) binds to genes that are activated during lytic reactivation. Correlation between BHLF1
and ChIP-seq derived high confidence targets of transcription factors is shown.
(G) Host proteins that interact with EBV proteins have their RNA transcripts upregulated during lytic reactivation, as shown by increased correlation with BHLF1.
See also Figure S4, Table S7, Table S8, and Table S9.
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hybrid protein interaction assays with EBV proteins as bait (Cal-
derwood et al., 2007) were correspondingly upregulated with
increased lytic gene expression (Figure 4G). Furthermore, we
found a small subset of host genes that may be coregulated by
multiple means. For instance, the WNT5B gene is bound by
EBNA1, is a member of the WNT pathway, and is commonly238 Cell Host & Microbe 12, 233–245, August 16, 2012 ª2012 Elsevidysregulated in human cancers, including chronic lymphocytic
leukemia (Lu et al., 2004; Lu et al., 2010).
The Host B Cell Lineage Regulator Pax5 Represses Viral
Oncogenes
We found that Pax5 binds with high occupancy to the viral
terminal repeats (Figure 5), which are known to regulate LMP1
through an unknown mechanism (Repic et al., 2010). Pax5 iser Inc.
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Figure 5. Pax5 Binds the Viral Terminal Repeats and Regulates Viral Oncogene Expression
(A) Pax5 and other transcriptional regulators bind the LMP control region. Pax5 binds the terminal repeats (TR) directly at two sites, as supported by ChIP-seq and
sequence motif. In the promoter, EBF1, PU.1, and SP1 were previously documented to cobind a GC-box element and regulate LMP1, while TCF12 has not been
reported previously.
(B) Pax5 binds with high occupancy at the TR locus compared with two known binding sites (EBV Wp promoter and human CD19 promoter) as determined by
ChIP-qPCR. We also confirm that Pax5 binds the TR in multiple latency types and EBV strains. MUTU presents type I latency and does not express LMP1,
whereas MUTU-LCL presents type III latency and expresses LMP1.
(C) Pax5 protein expression is depleted by two independent lentiviral shRNA constructs. Western blot of LCL infected with shPax5-1 or shPax5-2 lentivirus and
assayed 5 days after infection followed by puromycin selection.
(D) Western blot of BZLF1 and actin in shPax5-1- or shPax5-2-infected LCLs.
(E) Real-time qPCR analysis of EBV genome copy number relative to cellular actin. Values are normalized to shControl infected LCLs. Error bars indicate the SD
from the mean (n = 3).
(F) PFGE analysis of Raji cells infected with shControl, shPax5-1, or shPax5-2 for 5 days after infection and then analyzed by Southern blot analysis. Circular (C),
linear (L), and sublinear (SL) forms of the viral genome are indicated.
(G) Knockdown of Pax5 induces LMP1 and LMP2 while decreasing expression of EBNA1 and EBNA2. Pax5 depletion also leads to an increase in the BZLF1 lytic
activator. All transcripts are quantified by qRT-PCR and normalized to cellular actin. Error bars indicate the SD from the mean (n = 3).
See also Figure S5.
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Figure 6. Cohesin Regulates EBV Chromosome Conformation and Latent Cycle Gene Expression
(A) ChIP-seq profiles for chromatin structure protein CTCF and cohesin components (Smc3 and Rad21) demonstrate cobinding at several loci. Chromosome
conformation capture (3C) anchor and acceptor primers (shown above) were used to determine DNA loop structures of the viral episome.
(B) Co-occupancy of CTCF, Smc3, and Rad21 at LMP1 and OriP is accompanied by additional transcription factors JUND, BATF, TCF12, and EBF1 and histone
modifications.
(C) Identification of a DNA loop between CTCF-cohesin at LMP1 (166.5 kbp) and OriP (6–9.5 kbp). LCLs (top) subjected to 3C with MseI restriction
digestion show specific interaction between oriP and 166.5kbp (anchor). Positive control (bottom) was performed on bacmid ligation products, where all
permutations of acceptor sites and anchor are created. The assay is qualitatively specific to under 1 kbp, as shown by the multiple negative regions proximal
to OriP.
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Genomic Profiling of EBVa B cell-specific factor that plays an essential role in B cell devel-
opment and contributes to B cell tropism of EBV latency through
initial activation of the latency transcription program at Wp (Tier-
ney et al., 2000; Tierney et al., 2007). ChIP-seq analysis reveals
two major peaks of Pax5 in at least one, though possibly all, of
the viral terminal repeats (Figure 5A). Pax5 binding was validated
by real-time PCR with primers specific for terminal repeat (TR)
DNA, and a Pax5 consensus motif was identified within the
centers of the ChIP-seq peaks (Figures 5A, 5B, and S5A). We
also confirmed that Pax5 binds the TR in an alternative EBV
strain (Mutu) and in both type I (MutuI) and type III (Mutu-LCL)
latently infected cells (Figure 5B). Surprisingly, Pax5 binding at
the TR did not overlap with RNA polymerase II initiation factors,
suggesting that its function at the TR is more complex than prox-
imal promoter transcription repression. The Pax5 site in the TR is
distinct from the known binding sites for Pu.1 and Sp1 in the
LMP1 promoter (Sjo¨blom et al., 1995), which are identified by
ChIP-seq along with binding sites for Ebf1 and Tcf12 and are
the known sites of EBNA2 transactivation.
To explore the potential function of Pax5 in regulation of EBV
gene expression, we depleted Pax5 protein from LCLs using
lentivirus-delivered short hairpin RNA (shRNA). We identified
two different shRNA targeting sequences that effectively deplete
Pax5 protein at 5 days after lentivirus infection and selection (Fig-
ure 5C). We first assayed the effect of Pax5 on EBV lytic activa-
tion by monitoring BZLF1 protein expression by western blot
(Figure 5D) and EBV genome copy number by qPCR (Figure 5E).
We found that Pax5 depletion modestly (<2-fold) increased
BZLF1 protein expression (Figure 5D) and viral genome copy
number (Figure 5E). To assess the effect of Pax5 depletion on
EBV genome configuration, we assayed both LCL and Raji cells
for circularized and linear viral episomes by pulsed-field gel
electrophoresis (PFGE) (Figure 5F). PFGE analysis indicated
that Pax5 depletion had only marginal effects on EBV genome
copy number in LCL (Figure S5B). In contrast, a percentage of
viral episomes were converted to linear and sublinear genomes
in Raji cells (Figure 5F). Since Raji are defective for viral lytic
replication, these findings suggest that Pax5 may be important
for maintaining the circular episomal form of the genome during
latency.
To assess the effect of Pax5 depletion on viral transcription,
we measured EBV gene expression for LMP1, LMP2 isoform 1
(LMP2-1), LMP2 isoform 2 (LMP2-2), EBNA1, EBNA2, and the
lytic immediate early gene BZLF1. We found that Pax5 depletion
led to the activation of LMP1 and both isoforms of LMP2 while(D) The long-range interaction is highly robust and specific. 3C-qPCR shows a hig
of the bars represents the qPCR signal relative to positive control bacmid ligation
enzyme fragment, which is also given at the top of the plot. Error bars indicate th
(E) Depletion of cohesin components through lentiviral shRNA results in loss of
transduced with shControl (top), shSMC1 (middle), or shRad21 (bottom).
(F) Lentiviral shRNA constructs deplete protein expression for Smc1 and Rad21.
(G) Depletion of cohesin components activates transcription of latency genes. Exp
was assayed by qRT-PCR in LCLs infected with shSmc1, shRad21, or shControl
the mean (n = 3).
(H) Model depicting a DNA loop between the OriP and LMP loci, which is med
the terminal repeats.
OriP, latent origin of replication; FR, family repeats; DS, dyad symmetry repea
and Table S10.
Cell Hosdecreasing EBNA1 and EBNA2 transcript accumulation (Fig-
ure 5G). Pax5 depletion also increased BZLF1 transcription,
consistent with western blotting results (Figure 5D). These
findings indicate that Pax5 contributes to the regulation of EBV
transcription during latent infection.
Cohesin Mediates DNA Looping of the Viral Episome
To further explore viral chromosome architecture, we analyzed
ChIP-seq binding profiles for the chromatin structural factors
CTCF, SMC3, and Rad21 and observed a pattern of colocaliza-
tion (Figures 6A and S6). Most strikingwas the strong ChIP signal
at the convergence of the LMP1 termination site and LMP2 first
intron (Figure 6B). This positioning was highly reminiscent of the
CTCF-cohesin site identified within the latency transcript of the
KSHV genome (Stedman et al., 2008). Interestingly, Rad21 and
SMC3 also colocalized at the origin of latent replication (OriP),
which is known to be a central regulatory region for episome
maintenance and has been shown to regulate LMP1 through a
long-distance enhancer mechanism (Gahn and Sugden, 1995)
(Figure 6B).
As CTCF and cohesin have been implicated in long-distance
DNA looping interactions, we used the chromatin conformation
capture (3C) method to test whether the CTCF-cohesin sites
physically linked OriP with the LMP1/LMP2 locus (Supplemental
Experimental Procedures and Table S10). Using anchor primers
at the LMP1 locus and MseI digestion of the EBV genome, we
found a strong 3C linkage formed between the anchor and
positions centered around OriP (episome coordinates 6–9 kb)
but not at several proximal control regions or other regions
across the EBV genome (Figures 6C and 6D). These findings
were corroborated by DNA sequencing of the PCR amplified
junctions and by use of different primer sets for real time qPCR.
To test whether cohesin subunits have any effect on EBV gene
expression, we depleted SMC1 and Rad21 proteins using
shRNA. LCLs were infected with lentivirus expressing Rad21 or
SMC1 targeting shRNA and assayed by western blot for knock-
down efficiency (Figure 6F). Cohesin depletion led to a complete
loss of the 3C loop formed between the OriP and LMP1/LMP2
control regions (Figure 6E). qPCR analysis of EBV gene expres-
sion revealed that Rad21 or SMC1 depletion resulted in a general
increase of latency transcripts, including LMP1 and LMP2 (Fig-
ure 6G). Cohesin depletion also led to a modest increase in
BZLF1 expression. These results support the model that EBV
chromatin forms higher order structures that include loop forma-
tion between OriP and the LMP1/LMP2 locus and help maintain
viral latent cycle gene expression (Figure 6H).hly specific quantitative interaction with the region surrounding OriP. The height
products. The width of the bars demonstrates the size of the MseI restriction
e SD from the mean (n = 3).
long-range interaction. 3C-qPCR was as described in (D), except LCLs were
ression of EBNA1, EBNA2, LMP1, LMP2A, and BZLF1messenger RNA (mRNA)
. mRNA expression is normalized to shControl. Error bars indicate the SD from
iated by CTCF-cohesin binding sites and contains the Pax5 binding sites in
ts; EBER, EBV encoded RNA; Cp, BamHI C promoter. See also Figure S6
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Our work integrates large genomic data sets into a comprehen-
sive atlas of functional elements of a humanpathogen.We used a
strategy of large-scale computational analysis, hypothesis gen-
eration, and functional validation to dissect the complex factors
implicated in the regulation of both virus and host genes. Our
meta-analysis approach also reveals how large-scale projects
such as ENCODE and HapMap can have far-reaching scientific
impact in a field outside their original scope. We discovered
examples of coordinated mechanisms of viral gene control
through the combined analysis of nucleosome occupancy,
histone modification patterning, combinatorial transcription
factor binding, and long-range DNA looping. Several of these
mechanisms are reminiscent of those in the human genome
and illustrate the functional similarity of a virus and its host.
We provide insights into host-virus interactions through
combined genome-wide expression analyses. We aggregated
hundreds of RNA-seq experiments and observed many cell lines
displaying surprisingly high levels of early lytic-cycle genes
relative to late lytic-cycle genes. The correlation of this gene
expression program with EBV copy number suggests that abor-
tive lytic DNA replication may be an important mechanism for
viral genome maintenance and host cell population fitness.
Furthermore, analyses of virus and host transcriptomes revealed
unexpected coordination between viral lytic reactivation and
cellular pathways involved in B cell expansion and tumor promo-
tion. These findings are consistent with studies showing that viral
lytic-cycle gene expression correlates with EBV carcinogenesis
in humans (Dardari et al., 2000; Hanto et al., 1983) and con-
tributes to lymphomagenesis in a humanized mouse model
(Ma et al., 2011).
We also examine host-virus interactions at individual regula-
tory loci and provide insights into the relationship between chro-
matin organization, gene regulation, and how developmental
regulatory factors link these processes. The B cell identity factor
Pax5 was found to bind within the viral terminal repeats and
modulate transcription of viral oncogenes from within the DNA
loop connecting CTCF-cohesin peaks at LMP1 and OriP loci.
These binding sites are reminiscent of a similar coordination of
Pax5 and CTCF sites identified within the IgG locus, which func-
tion to direct class switching during B cell maturation (Ebert
et al., 2011). Pax5 mutations have been implicated in B cell
lymphomagenesis, which may result in dysregulation of LMP
expression in certain EBV malignancies, including Hodgkins’s
disease (McCune et al., 2006; Pasqualucci et al., 2001). Addi-
tionally, downregulation of Pax5 during typical germinal center
reaction may derepress LMP1 and LMP2, providing a mecha-
nism for virus-mediated rescue from apoptosis of somatically
hypermutated B cells that harbor tumorigenic translocations so
commonly seen in EBV-associated malignancies (Bechtel
et al., 2005; Klein and Dalla-Favera, 2008; Mancao et al., 2005;
Roughan and Thorley-Lawson, 2009). These observations
suggest that breakdown of host regulatory pathways for control-
ling EBV gene expression may contribute to tumorigenesis
through dysregulation of viral oncogenes.
EBV was discovered as the first human tumor virus nearly 50
years ago and was among the first genomes sequenced. It is
thus fitting that it serves as the prototype for functional genomic242 Cell Host & Microbe 12, 233–245, August 16, 2012 ª2012 Elseviand epigenomic elements in a human tumor virus, providing
a foundation for future work in viral genomics and the emerging
field of systems virology (Peng et al., 2009). We anticipate that
system-level and data-driven approaches will ultimately lead to
more comprehensive models of viral persistence and its role in
human cellular development and oncogenesis.
EXPERIMENTAL PROCEDURES
Aligning Reads to the Viral and Host Genomes
Data was aggregated from a variety of sources (Table S1) and aligned to the
EBV genome (GenBank accession number NC_007605, March 2010) using
the Bowtie program allowing for one mismatch. We ignore all reads that
aligned to the human genome, which ensured that all EBV reads are uniquely
EBV and not actually from similar host sequence. To subtract human reads, we
mapped all reads to hg19 (including all ‘‘Un’’ and ‘‘random’’ chromosomes),
using the same parameters as when aligning to the viral genome. The subtrac-
tion of human-aligning reads resulted in small regions of the EBV-genome
becoming unmappable (Figure S1).
Analysis of Transcription Factor Binding Sites
Transcription factor ChIP-seq peaks with significantly more reads than
IgG and input control sequencing experiments were identified. We modeled
reads in the control experiments by a Poisson distribution, and a p value of
1.72 3 107 was used as a cutoff for peak calling, which represents
a genome-wide familywise error rate of 0.01. Validation of a subset of
ChIP-seq peaks was performed as previously described (Tempera et al.,
2010). In brief, cells were fixed in 1% formaldehyde for 30 min, and DNA
was sonicated to between 200 and 350 base pairs. ChIP DNA was amplified
on an ABI Prism 7000 using SYBR green chemistry.
Estimation of Viral and Human Gene Expression
TopHat and Cufflinks were used to align reads and quantify known transcripts
(Trapnell et al., 2010). Transcript abundances were normalized by reads
per kilobase per million (RPKM). Human transcripts were taken from RefSeq
annotations for hg19. Multimapping reads were allowed to map to 30 regions
in the transcriptome before being ignored. RPKM values were normalized to
account for multimapping reads. Gene abundance was estimated as the
sum of all transcript isoforms. The per-million normalization was done relative
only to reads mapping to EBV or human, since this ensured independence of
transcript quantification in EBV and human. Use of absolute transcript quanti-
ties (normalized to total alignable reads in both EBV and human) is used only
when noted. RNA-seq experiments with low read count (less than 1 million
alignable human reads) samples were removed, and technical replicates
were averaged. From the original 294 RNA-seq assays, we obtained 201
reliable and independent samples.
Chromatin Conformation Capture
Chromatin conformation capture was performed as previously described
(Hage`ge et al., 2007; Tempera et al., 2011) with minor modifications. In brief,
cells were put through a 70 mm filter to obtain single cells. Ten million cells
were fixed in 1% formaldehyde for 30 min, and the reaction was quenched
with 0.125 M glycine. Cells were centrifuged, resuspended in lysis buffer,
and lysed for 10 min. Nuclei were collected and digested with 500 U MseI
restriction enzyme overnight at 37C. The digestion was halted by incubation
at 65C in 1.6% SDS on a 1,200 RPM shaker. The sample was diluted 10-fold,
followed by ligation reaction containing 100 U T4 DNA ligase for 4 hr at 16C
and 45 min at room temperature. The sample was digested by 300 mg
proteinase K at 65C overnight, followed by RNase treatment for 1 hr at
37C. DNA was phenol-chloroform extracted and ethanol precipitated and
analyzed with PCR, qPCR, and sequencing. As a control, the EBV bacmid
was MseI digested and ligated, thus creating all possible ligation products at
background concentrations.
Micrococcal Nuclease Digestion
Nuclei were isolated from 5 3 107 Mutu and Mutu-LCL cells with a Dounce
homogenizer in 4 ml lysis buffer (0.3 M sucrose, 2 mM magnesium acetate,er Inc.
Cell Host & Microbe
Genomic Profiling of EBV3 mM CaCl2, 1% Triton X-100, and 10 mM HEPES [pH 7.9]). The lysate was
centrifuged through a glycerol cushion (25% glycerol, 5 mM magnesium
acetate, 0.1 mM EDTA, and 10 mM HEPES [pH 7.4]) at 1,000 g for 15 min at
4C. The nuclei were incubated with micrococal nuclease I (500 U/ml) at
37C for 20 min in 200 ml digestion buffer (25 mM KCl, 4 mM MgCl2, 1 mM
CaCl2, 50 mM Tris [pH 7.4], and 12.5% glycerol). The reaction was stopped
by equal volume of stop buffer (2% SDS, 0.2 M NaCl, 10 mM EDTA, 10 mM
EGTA, 50 mM Tris [pH 8.0], and proteinase K [100 mg/ml]) for 2 hr at 50C.
Micrococcal nuclease I (MNase I) resistant DNA was extracted by phenol-
chloroform and ethanol precipitation. The 150 bp mononucleosomal DNA
was isolated from 1.5% agarose gel and purified by the QIAquick Gel extrac-
tion kit (QIAGEN) according to the manufacturer’s protocol. Purified DNA was
then subject to Solexa sequencing according to the manufacturer’s recom-
mendations (Illumina).
Lentiviral Delivery of shRNA
Lentiviral shRNAs were obtained from the Sigma-Aldrich MISSION shRNA
library. Four million Mutu-LCL cells were passed through a 40 mm filter, spun
down, and resuspended in 2 ml lentivirus suspension. Cells were spun at
500 g for 90 min at 25C. Cell were cultured at 500,000 cells/ml for 5 days
with media changes in 1 mg/ml puromycin. Knockdown was confirmed by
western blot and qRT-PCR.
Pulsed-Field Gel Electrophoresis
For resolution of large viral genomic DNA fragments, PFGE was performed as
described previously (Dheekollu and Lieberman, 2011). In brief, DNAmigrated
for a duration of 23 hr at 14C with the pulse ramping linearly every 60–120 s
through 120C using a Bio-Rad CHEF Mapper.
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